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 Summary
  Chordomas are rare tumors that can develop anywhere along the craniospinal axis. These tumors 
present challenges with respect to diagnosis and treatment due to a high rate of recurrence, even 
after multiple surgeries, and the propensity to involve any region within the craniospinal axis. 
New developments in radiation therapy have improved recurrence-free survival in patients with 
chordomas. Different regimens of chemotherapy and molecularly-targeted therapies, as adjuvants 
to surgery, have been described in individual case reports and case series. The purpose of this 
paper is to describe a case of clival chordoma and review recent developments in diagnostic and 
therapeutic options.
  A 77-year-old female was referred because of diplopia and progressively worsening headaches. 
Head imaging revealed a large expansile and erosive mass in the skull base. The patient underwent 
a successful endoscopic endonasal trans-sphenoidal resection of the mass, with biopsy confirming 
the diagnosis of chordoma. Postoperatively, the patient experienced an improvement in neurological 
symptoms.
  Chordomas can present a diagnostic challenge due to the rare occurrence and a tendency to involve 
any region within the craniospinal axis.
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Chordomas, which are remnants of the notochord, origi-
nate from the bone and can occur anywhere along the 
craniospinal axis. The incidence rate of chordomas is 0.08 
per 100,000, with a higher incidence rate of 0.1 in males, 
versus 0.06 in females. These tumors are rare in patients 
younger than 40 years [1]. About 32% of chordomas occur 
intracranially, 32.8% are spinal and 29.2% sacral [1]. 
Chordomas can present a diagnostic challenge due the rare 
prevalence and a tendency to involve any region within the 
craniospinal axis. Similarly, their location can present a 
therapeutic challenge, since they may not be amenable to 
surgical resection. In this paper, we describe a case of clival 
chordoma, discuss various diagnostic modalities available 
to differentiate chordomas from other tumors, and describe 
therapeutic options including adjuvants.
Case Report
A 77 year-old female presented with a one-year long his-
tory of progressively worsening headaches, along-with a 3 
month history of double vision. The headache was of a dull, 
aching character, fluctuated in intensity, was only partially 
relieved by acetaminophen, and was non-positional.
The patient was seen in the ophthalmology and neurosur-
gery clinics. The visual field testing and ophthalmologic 
exam, including a fundoscopic exam, were normal except 
for right abducens palsy. In the neurosurgical clinic, a neu-
rological exam was remarkable only for the right abducens 
palsy.
A CT scan of the sinuses was obtained (Figure 1) which 
revealed a large, expansile, erosive mass within the midline 
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sphenoid sinus. It measured more than 3 cm in all dimen-
sions. The mass was isodense and filled the sphenoid 
sinus completely, eroding it inferiorly and extending into 
the right pneumatized pterygoid. The left pterygoid pro-
cess was also pneumatized, but did not accommodate the 
mass. The mass was also eroding into the superior aspect 
of the clivus, and extended into the posterior fossa. It had 
scattered calcifications, which likely represented erosion 
of the native bone. Brain MRI performed before and after 
administration of 14 ml of contrast (Magnevist) revealed a 
large mass involving the clivus and the sphenoid sinus, pre-
dominantly on the right and with the same characteristic 
findings as on CT (Figure 2). The mass was hyperintense on 
T2-weighted images, mildly hypointense on T1-weighted 
images, and showed heterogeneous enhancement.
The patient underwent endoscopic endonasal trans-sphe-
noidal skull base surgery with total resection of the mass. 
The diagnosis was confirmed with a perioperative biopsy 
result, which showed lobules separated by collagenous 
bands, enclosing physalipharous cells in a myxoid matrix. 
The physalipharous cells were glycogen and mucin-laden, 
thus classifying it as a conventional chordoma.
After surgery, an improvement in diplopia and headache 
was observed. The postoperative non-contrast CT (Figure 3) 
of the nasal cavity and paranasal sinuses showed residual 
air and packing material, but no hemorrhage or abnormal 
fluid collections. MRI performed 2 days after resection, 
with and without contrast (14 ml of Magnevist), revealed 
a thin rim of irregularly enhancing soft tissue superiorly, 
most likely representing postoperative soft tissue changes 
or minimal residual tumor, and a hyperintense cystic mass 
located superiorly (Figure 4). At one-year follow-up, the 
patient was free of tumor recurrence.
Discussion
Chordomas can have varied presentations, depending on 
their location. A cranial tumor may present with chronic 
Figure 1.  CT of the nasal cavity and paranasal sinuses performed without contrast. There is a large isodense mass centered in the sphenoid sinus and 
sella (encircled in A) with scattered calcifications (arrows in B). The mass fills the sphenoid sinus eroding it inferiorly. It extends into the 
right pneumatized pterygoid (arrowheads in C). There is also extension into the posterior fossa with effacement of the prepontine cistern 
and involvement of both cavernous sinuses.
A B C
Figure 2.  MRI examination of the brain and pituitary gland performed before (A) and after (B) administration of 14 ml of Magnevist intravenous 
contrast. A large mass involves the upper portion of clivus and the sphenoid sinuses can be observed. The mass extends to involve 
the pneumatized portion of the right sphenoid sinus. The internal septations correspond to the calcifications observed on the CT scan 
(Figure 1), suggesting an internal calcified matrix. The mass abuts both cavernous carotid arteries (arrowheads, C). Scattered foci of 
hyperintense T2 and FLAIR signals are also observed in the white matter, suggestive of mild microangiopathy (arrow in C).
A B C
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intractable headaches, cranial neuropathy (as in our patient 
who had right abducens palsy), and other rarer symptoms 
such as subarachnoid hemorrhage, cerebrospinal fluid rhi-
norrhea, and epistaxis [2]. Tumors located along the spine 
may result in back pain (which may be dermatomal in 
nature), sphincter dysfunction, lower extremity weakness, 
and paresthesias. Various imaging modalities assist in the 
differential diagnosis. Plain radiographs may reveal local 
bony erosion and scattered calcifications. On CT, chordo-
mas have decreased attenuation and hyperdense regions, 
may demonstrate erosion of nearby structures and exhibit 
an inner calcified matrix. On brain MRI, bony expansion is 
a typical feature, along with hypointensity on T1-weighted 
images and hyperintensity on T2-weighted images. 
There may be a heterogeneous enhancement pattern on 
T1-weighted images after administration of gadolinium. 
Final diagnosis can only be made based on a perioperative 
biopsy, using various analytical techniques. The differential 
diagnosis and the distinguishing features of masses in the 
skull base are listed in Table 1.
Figure 3.  (A, B) CT scan of the brain performed with Stryker protocol without administration of intravenous contrast; status post trans-sphenoidal 
approach for resection of a large skull base mass. The mass is resected with residual air and packing material observed.
A B
Figure 4.  MRI of the brain obtained using a pituitary protocol, 14 ml of Magnevist was administered; status post trans-sphenoidal resection of a 
large mass at the skull base. A thin rim of irregularly enhancing soft tissue is observed at the resection site, most pronounced superiorly. A 
T2 hyperintense signal is observed (arrow) without enhancement and likely represents cystic changes.
A B
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Histopathology
Chordomas can be divided into three different types. 
Conventional chordomas are slow-growing tumors that 
have physalipharous cells within a myxoid stroma and 
may show cellular proliferation, as evidenced by numerous 
mitoses, nuclear pleomorphism, and presence of nucleoli 
[3]. These demonstrate reactivity for the S100 protein, epi-
thelial membrane antigen, vimentin, and cytokeratins. The 
chondroid variety shows areas of chondroid differentiation 
within an otherwise histologically indistinct conventional 
chordoma [3]. The dedifferentiated variety exhibits a high-
grade sarcoma in combination with conventional or chon-
droid chordoma, and may be associated with a worse prog-
nosis than other subtypes [3]. The dedifferentiated compo-
nent is rapidly growing, can lead to metastatic spread, and 
signals disease progression [4].
Brachyury is a transcription factor that is involved in noto-
chord development and is a very specific marker for both 
notochord and notochord-derived tumors [5]. Brachyury 
has been shown to be expressed in all chordomas inves-
tigated in a study including both chordoid and chon-
droid components, whereas it was not detected in any 
of the other analyzed tumors [5]. Chondrosarcoma does 
not express brachyury and therefore this biomarker can 
be used to distinguish chordoma from chondrosarcoma. 
Brachyury expression is also used to distinguish chordoma 
from germ cell tumors and metastatic clear cell renal car-
cinoma [6]. Brachyury is not detected in nucleus pulposus, 
which could suggest a different origin for nucleus pulpo-
sus than notochord alone [5]. Presence of MIB1 and p53 
staining also has diagnostic and prognostic significance, 
indicating proliferative activities in chordomas as well as 
other central nervous system tumors [7], with MIB1 close-
ly following p53 expression [8]. Epidermal growth factor 
receptor (EGFR) expression has been found in 69% of chor-
doma cases, and tyrphostin (EGFR inhibitor) reduced pro-
liferation of a chordoma cell-line in-vitro; hence, EGFR is 
a potential therapeutic target [9]. Other molecular markers 
Diagnosis Plain radiograph MRI CT
Chondrosarcoma May appear translucent 
and expansile with matrix 
calcifications. About half are lytic. 
Endosteal scalloping may be seen
Lesions are lobulated and 
have low signal on T1- and 
high intensity on T2-weighted 
sequences. Heterogeneous 
enhancement with contrast. 
Calcifications may appear as 
signal voids
May appear as a translucent 
soft tissue mass with matrix 
calcifications, endosteal 
scalloping, and exhibit 
heterogeneous enhancement 
with contrast
Pituitary macroadenoma Unable to identify soft tissue mass Appears isointense on T1 and 
T2, but posterior lobe may be 
hyperintense on T2. Moderate 
enhancement seen on gadolinium 
contrast. Imaging mode of choice
Appears solid and isodense 
to brain, rare calcifications, 
may involve adjacent bony 
components
Chordoma Unable to identify soft tissue 
masses but can show lytic lesions 
with irregular calcifications
Low signal is observed on T1 with 
areas of high signal intermixed 
that may represent hemorrhage. 
High signal on T2. Heterogeneous 
enhancement is seen after 
administration of gadolinium. 
Differentiation from chondroma 
may be challenging
Appears as an isodense, well-
demarcated soft tissue mass that 
is lytic and locally destructive. 
Has irregular calcifications, 
and heterogeneous contrast 
enhancement. Destruction of 
several vertebrae may be seen in 
case of spinal involvement
Osteosarcoma A soft tissue mass causing bony 
destruction is seen. Periosteal 
and lamellated reaction are also 
sometimes visualized. Variable 
calcification can be observed
The best imaging modality 
to assess local spread, soft 
tissue involvement, and tumor 
extension. The soft tissue 
component has intermediate 
signal on T1 and high signal on 
T2. Solid components typically 
enhance with contrast on T1
May assist in diagnosis, when 
plain radiographs are unclear. 
Especially useful for identifying 
mineralized bony matrix 
which can be missed on plain 
radiographs and MRI
Hemangiomas Vertebral hemoangiomas have 
thickened vertical trabeculation; 
Calvarial hemangiomas are 
osteolytic and have trabeculae in 
a “sun-burst” pattern
Hyperintense signal on T2-
weighted MRI corresponds to 
increased vascularity. Hypointense 
signal on both T1 and T2 is 
characteristic of thickened 
vertebral trabeculae
Thickened vertebral trabeculae 
are seen in better detail than 
on plain radiographs. Bony 
destruction may be seen
Table 1. Imaging characteristics of various tumors at the skull base.
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within chordomas have been investigated, such as AKT, 
mTOR, and TSC; it was noted that 65% of chordomas that 
were studied may respond to mTOR and AKT inhibitors 
[10]. Genetic analysis also offers significant prognostic 
information. De novo chordomas with a normal karyotype 
were noted to have a recurrence rate of only 3% in a study 
investigating karyotypes of chordomas from 64 patients, 
whereas an abnormal karyotype resulted in a recurrence 
rate of 45% and signaled disease progression and poor out-
comes [11]. The most important karyotype abnormalities 
are duplications on 6q27 and brachyury gene [11].
Medical treatment
Imatinib, a tyrosine kinase inhibitor currently approved 
as monotherapy for chronic myelogenous leukemia, has 
been investigated in chordomas, and its use has been asso-
ciated with tumor liquefaction and a decreased density of 
chordomas expressing the platelet-derived growth factor 
receptor-beta (PDGFRB) [12]. It has also proved efficacious 
in treatment of clival metastases from other tumors. For 
instance, in a patient with a clival metastasis of gastro-
intestinal stromal tumor, treatment with imatinib result-
ed in decreased diplopia [13]. In a phase-II study, of 50 
patients with PDGFRB positive chordomas who received 
imatinib, 35 patients had stable disease, with a clinical 
benefit rate of 64% and median progression-free survival 
of 9 motnhs [14]. Combined use of imatinib and sirolimus 
(rapamycin) – an immunosuppressant that directly inhib-
its the mammalian target of rapamycin (mTOR), has been 
studied in patients with chordomas that are resistant to 
imatinib. In a series of 9 patients with secondary resistance 
to imatinib, the combined use of imatinib and sirolimus 
resulted in a partial response in 7 patients, stable disease in 
1 patient, and progressive disease in 1 patient, with a clini-
cal benefit rate of 89% [15]. Cisplatin has also proven effi-
cacious in tumor response and shrinkage amongst patients 
who developed secondary resistance to imatinib [16]. 
In a report of a 19-month-old girl with malignant cervi-
cal chordoma with pulmonary metastases, a multi-agent 
chemotherapeutic regimen involving systemic ifosfamide 
and doxorubicin combined with intrathecal hydrocorti-
sone, cytarabine, and methotrexate was found to be effec-
tive [17]. Another case report demonstrated that a differ-
ent chemotherapeutic regimen consisting of isotretinoin, 
interferon-A, thalidomide, and doxorubicin was effica-
cious in slowing progression of metastatic clival chordoma 
[18]. Cetuximab and geftinib have also been demonstrated 
to cause partial response in a patient with sacral chordo-
ma and pulmonary metastasis, whose biopsy had shown 
expression of epidermal growth factor receptor [19].
Surgery
Surgical intervention is the recommended treatment 
modality, with an aim to achieve a gross total resection of 
the tumor. The endoscopic endo-nasal trans-sphenoidal 
approach is the preferred mode of surgery for suspected 
chordomas and chondrosarcomas of the clivus, as in our 
case [1]. This technique is minimally invasive and has an 
efficacy similar to open surgery for clival chordomas [20]. 
Other approaches have been described in the literature, 
including trans-mandibular, subtemporal-preauricular, 
extreme lateral transcondylar, and transcochlear; how-
ever, complete resection in all cases is difficult and local 
recurrence may occur [21]. The primary goal of surgery 
is to achieve primary radical resection, followed by adju-
vant treatments. This approach has been shown to improve 
long-term outcomes and recurrence-free rates [22,23], 
similar to other brain tumors such as glioblastoma multi-
forme, when compared to surgery alone [24]. Surgery is fre-
quently combined with adjuvant radiation therapies such 
as gamma knife surgery and has been shown to result in a 
satisfactory long-term control of chordomas [25,26].
Radiation treatment
Radiation therapy is best offered in combination with 
aggressive surgical resection. Several modes of adjuvant 
radiation therapy have been rigorously investigated. The 
proton and photon beam therapies improve outcomes in 
patients with chordomas, chondrosarcomas, ocular malig-
nancies, and sinonasal tumors, with a 5-year local control 
rate of 50-65% for photon beam and 81% for proton ther-
apy, respectively [27]. In a study of 8 patients with chor-
domas or chondrosarcomas of the skull base and a median 
tumor volume of 40 cm3 who received a median dose of 63 
Gy of proton beam therapy, a survival rate of 100% was 
reported with local control rate of 100% for chordomas and 
86% for chondrosarcomas over a 3 year follow-up [28]. No 
toxicities such as optic neuropathy and brain stem injury 
were reported [28]. For patients with spinal chordomas and 
chondrosarcomas who had undergone resection, the over-
all survival rate was 93.3%, and local control rate was 58% 
at 2 years after treatment, with a median dose of 70 Gy in 
the case of proton therapy [25]. Proton beams have a larg-
er mass, straighter trajectories, and more effective energy 
deposition than photon beams, and they cause less damage 
to the surrounding critical structures. Carbon ion radiother-
apy has also been studied in 38 patients with sacral chordo-
mas who had a median age of 66 years, median tumor vol-
ume of 523 cm3, received a median dose of 70.4 Gy, and had 
a median follow-up of over 80 months [29]. The 5-year sur-
vival rate was 86%, the 5-year local control rate was 89%, 
and only minimal complications were reported [29]. In a 
cohort of 155 patients with skull base chordomas who were 
treated with carbon ion irradiation at a median total dose 
of 60 Gy, the 10-year local control was 54% and the 10-year 
overall survival was 75% [30]. Experience with CyberKnife 
stereotactic radiosurgery has been reported in 18 patients 
with a median tumor volume of 128 cm3, who had received 
a median dose of 35 Gy and had a median follow-up of 46 
months [31]. The local control rate was 59.1% at 65 months, 
and the survival rate was 74.3% [31].
Prognosis
The available data regarding prognosis varies and depends 
on the source of reports, definitions of survival and recur-
rence-free rates, treatment modality, and duration of fol-
low-up. The respective survival rates at 5 and 10 years 
of follow-up have been estimated to be 67.6% and 39.9%, 
respectively in one report [1]. In another report, these fig-
ures were 47% and 27% for no treatment, 33% and 16% 
for surgery alone, 69% and 34% for radiotherapy alone, 
and 75% and 59% for combination therapy [24]. As more 
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treatment modalities are developed and longer-term follow-
ups are available, the survival rates are likely to change.
Conclusions
Chordomas are rare tumors of a notochordal origin that 
often have an insidious onset. As they progress, they cause 
local destruction, and hence neurological deficits. Early 
diagnosis is essential, as aggressive surgical resection fol-
lowed by adjuvant therapy improves long-term outcomes. 
In this review, we described a case of clival chordoma 
and discussed various diagnostic methods to differentiate 
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